Needles Out, Pumps In: Modular’s Pivot and Insulet’s Omnipod Seek To Rewrite the Diabetes Playbook -( $MODD $PODD )

Wall Street is quietly drafting a new chapter in diabetes technology, and investors may want to read every line: Modular Medical (NASDAQ: MODD) and Insulet Corporation (NASDAQ: PODD) are positioning tubeless insulin pumps not as gadgets, but as infrastructure for a chronic epidemic that is still very much in expansion mode.

---

A Growing Epidemic Meets A Hardware Problem

More than 40 million Americans are living with diabetes today, roughly 12% of the U.S. population, and an estimated 1.5 million more are diagnosed every year. Over 2 million Americans live with type 1 diabetes, with insulin not as an option, but as a daily requirement. Yet despite this scale, the hardware story is surprisingly underpenetrated: roughly 4.8 million people in the U.S. require daily insulin, but only about 20% use an insulin pump, leaving the vast majority on multiple daily injections and an addressable, multi‑billion‑dollar gap in pump adoption. This mismatch—high prevalence, low device adoption—is precisely where Wall Street’s attention is starting to migrate, from drugs alone to durable, recurring‑revenue technology platforms.

---

Modular Medical (MODD): Shipping Simplicity Into

Modular Medical (NASDAQ: MODD) has now moved from promise to physical product, announcing that its Pivot tubeless insulin patch pump starter kits are shipping to multiple endocrinology practices and physician offices for training and patient introduction. Pivot recently secured FDA 510(k) clearance and now enters the U.S. market as only the second fully electronic, tubeless insulin pump available, giving MODD a differentiated seat at a small but strategically important table..

The Pivot pump is purpose‑built for adults with diabetes who are currently on multiple daily injections and have previously balked at traditional pump systems due to cost, complexity, and usability concerns—MODD’s self‑described “almost‑pumpers,” estimated to represent about 70% of insulin‑dependent adults. With a removable two‑part design, a 3 mL reservoir, and no need for battery recharging, the device is engineered to reduce friction at every step, aiming to convert reluctance into adoption and injections into recurring device revenue.

MODD’s plan is intentionally disciplined rather than splashy: full commercial launch will roll out in phases, beginning with select high‑volume endocrinology practices and expanding across metropolitan markets by late 2026, supported by an initial manufacturing capacity of roughly 6,000 users and a scalable low‑cost platform designed for rapid ramp. For investors, that phased strategy reads less like a startup sprint and more like a capital‑efficient call option on broader U.S. pump penetration—and, ultimately, international expansion once CE mark approval is targeted in late 2026 or early 2027.

---

Insulet (PODD): Boardroom Reinforcements For A Global Tubeless Franchise

Insulet Corporation (NASDAQ: PODD), already the global leader in tubeless insulin pump technology through its Omnipod brand, is leaning into governance and strategic oversight as competition in tubeless pumps heats up. The company recently announced the appointment of Jonathan (“Jay”) Mazelsky as an independent director, effective July 1, 2026, bringing to the board a track record of translating science into commercial solutions that drive durable growth and shareholder value. Insulet’s leadership has framed the addition as part of a larger effort to expand access and further strengthen Omnipod’s leadership position worldwide, at a time when diabetes prevalence continues to climb and device penetration is still far from saturation. With over 40 million Americans living with diabetes and tens of millions more sitting in the prediabetes queue, the addressable pump market is not simply large—it is structurally replenished every year. For PODD shareholders, strengthening the board with commercially minded scientific leadership looks less like window dressing and more like a pre‑emptive move to defend and extend a category that MODD and others are now actively entering.

---

The Investment Narrative: From Injections To Installed Base

From an investor’s lens, the diabetes device market is evolving from a niche accessory story into an installed‑base, razor‑and‑razor‑blade model tied to a chronic condition with rising prevalence and significant economic impact. Diagnosed diabetes alone carries an estimated annual cost north of $400 billion in the U.S., including more than $300 billion in direct medical expenses—a cost structure that increasingly incentivizes payers and providers to favor technologies that improve adherence and outcomes.

Against this backdrop, MODD’s Pivot aims to convert the 80% of daily‑insulin users still on injections into pump customers by lowering cost and complexity barriers, positioning the company at the front end of underpenetrated demand. Insulet, by contrast, is managing a global, established tubeless franchise, adding governance firepower to maintain Omnipod’s leadership as competition intensifies and as new players assert that “simple, affordable, flexible” pumps can attract hesitant users. In practical terms, that sets up a two‑track narrative: MODD as an emerging commercial‑stage player with high operating leverage to incremental adoption, and PODD as a scaled incumbent using strategic appointments to protect its moat and extend its runway. For investors attentive to secular health trends, both names sit within the same structural theme—the long transition from injections to smart, tubeless, connected delivery—but at very different points along the risk‑reward curve.

---

Diabetes Tech As A Long‑Duration Theme

With diabetes prevalence climbing from roughly 10% of the U.S. population two decades ago to over 11% today and more than 40 million Americans now living with the disease, the macro trend is not subtle. Each year adds new patients and incremental demand for insulin and delivery technologies, while a large installed base continues to navigate cost, access, and adherence challenges that tubeless pumps aim to mitigate.

The investment question is less whether diabetes technology will grow, and more who will own the most valuable share of that growth: early‑stage innovators like Modular Medical (MODD), targeting “almost‑pumpers” with a simplified tubeless solution now shipping into endocrinology offices, or global leaders like Insulet (PODD), reinforcing boardroom expertise to defend and scale a mature tubeless franchise. In a market where only about one in five daily‑insulin users currently relies on a pump, the runway is long enough to accommodate more than one winner—but not necessarily for the complacent. For investors crafting exposure to diabetes technology, the emerging story is not just about devices; it is about platforms, recurring revenue, and the slow but steady migration of millions of patients from syringes to software‑enhanced, tubeless hardware. As MODD begins its commercial journey and PODD refreshes its strategic bench, the space offers an unusually clear combination of secular growth, underpenetration, and differentiated competitive positioning—a combination that tends to age well in long‑term portfolios.

Learn More

Paul DiPerna, founder of Modular Medical, Inc and legacy inventor of insulin pumps and other medical devices, shares why he created the Pivot™ Insulin Delivery System and potential advantages of Pivot™ compared to daily insulin injections.

The Sources

1. Modular Medical Announces Shipment of Pivot Tubeless Patch Pumps – Accesswire via Morningstar
   https://www.morningstar.com/news/accesswire/1181878msn/modular-medical-announces-shipment-of-pivot-tubeless-patch-pumps[morningstar]
2. Modular Medical Starts Shipping Pivot Pumps to Doctors’ Offices – StockTitan
   https://www.stocktitan.net/news/MODD/modular-medical-announces-shipment-of-pivot-tubeless-patch-q6kcn0c2fej5.html[stocktitan]
3. Modular Medical Launches Pivot Tubeless Insulin Patch Pump – Drug Delivery Business News
   https://www.drugdeliverybusiness.com/modular-medical-launches-pivot-tubeless-pump/[drugdeliverybusiness]
4. Modular Medical Announces Commercial Availability of Pivot Tubeless Insulin Patch Pump – Access Newswire
   https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/modular-medical-announces-commercial-availability-of-pi[accessnewswire]
5. Only 20% Use Insulin Pumps – Modular Medical / Tribe Public CEO Event Note – StockTitan
   https://www.stocktitan.net/news/MODD/registration-is-now-open-for-tribe-public-s-ceo-presentation-and-q-a-7758uuxd5eia.html[stocktitan]
6. Insulet Announces Appointment of Jonathan J. Mazelsky to Its Board of Directors – Insulet Investor Relations
   https://investors.insulet.com/news/news-details/2026/Insulet-Announces-Appointment-of-Jonathan-J–Mazelsky-to-its-Board-of-Direc[investors.insulet]
7. National Diabetes Statistics Report – CDC
   https://www.cdc.gov/diabetes/php/data-research/index.html[cdc]
8. Diabetes in America: Prevalence, Statistics, and Economic Impact – American Diabetes Association
   https://diabetes.org/about-diabetes/statistics/about-diabetes[diabetes]
9. Diabetes Statistics – NIDDK
   https://www.niddk.nih.gov/health-information/health-statistics/diabetes-statistics[niddk.nih]
10. How Many Americans Have Diabetes? – USAFacts
    https://usafacts.org/articles/how-many-americans-have-diabetes/[usafacts]
11. Insulin Statistics: Costs, Usage & Diabetes Rates – SingleCare
    https://www.singlecare.com/blog/news/insulin-statistics/[singlecare]